[HTML][HTML] Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors
JJ Luke, JM Lemons, TG Karrison… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
JJ Luke, JM Lemons, TG Karrison, SP Pitroda, JM Melotek, Y Zha, HA Al-Hallaq, A Arina…
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.govPurpose Stereotactic body radiotherapy (SBRT) may stimulate innate and adaptive immunity
to augment immunotherapy response. Multisite SBRT is an emerging paradigm for treating
metastatic disease. Anti-PD-1–treatment outcomes may be improved with lower disease
burden. In this context, we conducted a phase I study to evaluate the safety of
pembrolizumab with multisite SBRT in patients with metastatic solid tumors.
to augment immunotherapy response. Multisite SBRT is an emerging paradigm for treating
metastatic disease. Anti-PD-1–treatment outcomes may be improved with lower disease
burden. In this context, we conducted a phase I study to evaluate the safety of
pembrolizumab with multisite SBRT in patients with metastatic solid tumors.
Abstract
Purpose
Stereotactic body radiotherapy (SBRT) may stimulate innate and adaptive immunity to augment immunotherapy response. Multisite SBRT is an emerging paradigm for treating metastatic disease. Anti-PD-1–treatment outcomes may be improved with lower disease burden. In this context, we conducted a phase I study to evaluate the safety of pembrolizumab with multisite SBRT in patients with metastatic solid tumors.
ncbi.nlm.nih.gov